MR

Michael Rome

Managing Director & Head of Therapeutics Investing at Foresite Capital

Los Angeles Metropolitan Area

VC
Investor

Invests in

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Project Management
Presentation Development
DCF Valuation
Equity Valuation
Business Valuation
Intellectual Property Valuation
Financial Modeling
Business Modeling
Biotechnology
Private Equity
Venture Capital

Education

Lists including Michael

AS
AJ
AA
AC

Based in LA

588 people

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Investments

Alumis

Series A

Total Funding: $330M

Remix Therapeutics

Series A

Total Funding: $210M

CG Oncology

Series F

Total Funding: $110M

XinThera

Series B

Total Funding: $50M

Theseus Pharmaceuticals

Series B

Total Funding: $100M

Kinnate Biopharma

Series A

Total Funding: $200M

Nurix Therapeutics

Private Equity

Total Funding: $150M

Work Experience

FC
Foresite Capital

2016

  • Managing Director

    2016

RayThera

2023

  • Board Member

    2023

CO
CG Oncology

2023

  • Board Observer

    2023

AT
Avenzo Therapeutics

2022

  • Board Member

    2022

KB
Kinnate Biopharma Inc.

2018

  • Board Member

    2018

A
Alumis

2021

  • Board Member and Observer

    2021

RT
Remix Therapeutics

2020

  • Board Member

    2020

XinThera Inc.

2021 - 2023

  • Board Member

    2021 - 2023

AI
Affinivax Inc.

2021 - 2022

  • Board Observer

    2021 - 2022

TP
Turning Point Therapeutics

2018 - 2019

  • Board Observer

    2018 - 2019

    Co-led series D financing